Interaction between ketoconazole, amphotericin B and terbinafin and three diazenumdiolates in concomitant uses against some fugal species

Daru

Volumn 14, Issue 2, 2006, Pages 87-92

  Falahati, Mehraban ^b   Shabani, Mohammad ^b   Rodaki, Maryam M A ^b   Jahaniani, Fereshteh ^a   Bagheri, Kamran Porshang ^b   Ebrahimi, Soltan Ahmed ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amphotericin B; Antifungal activities; Diazeniumdiolates; Ketoconazole; NO; Terbinafine

Indexed keywords

1 [N(2 AMINOETHYLE)N(2 AMINOETHYLE)AMINO]DIAZEN 1 IUM 1,2 DIOLATE; 3,3 (HYDROXYNITROSOHYDRAZINO)BIS 1 PROPANAMINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; KETOCONAZOLE; NITRIC OXIDE DONOR; SODIUM 1 N,N DIETHLAMINEO; TERBINAFINE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CRYPTOCOCCUS NEOFORMANS; DERMATOPHYTE; DRUG ANTAGONISM; DRUG HALF LIFE; DRUG POTENTIATION; FUNGUS; IN VITRO STUDY; LC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 33745663071     PISSN: 15608115     EISSN: 15608115     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kwon KS, Jang HS, Son HS, et al. Widespread and invasive Trichophyton rubrum infection mimicking Kaposi's sarcoma in a patient with AIDS. J Dermatol. 2004; 31:839-43.
2. Martinez M, Lopez-Ribot JL, Kirkpatrick WR, et al. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother. 2002; 49:515-24.
3. Safdar A, Hanna HA, Boktour M,. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer. 2004; 101:2859-65.
4. Perfect JR, Management of invasive mycoses in hematology patients: current approaches. Oncology (Huntingt). 2004; 18:5-14.
5. Sung JM, Ko WC, Huang JJ,. Candidaemia in patients with dialysis-dependent acute renal failure: aetiology, predisposing and prognostic factors. Nephrol Dial Transplant. 2001; 16:2348-56.
6. Ischiropoulos H, Gow A,. Pathophysiological functions of nitric oxide-mediated protein modifications. Toxicology. 2005; 208 (2):299-303.
7. Revankar SG, Dib OP, Kirkpatrick WR, et al.Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clinical Infectious Diseases 1998; 26:960-3.
8. Rex JH., Rinaldi MG, Pfaller MA,. Resistance of Candida species to fluconazole. Antimicrobial Agents and Chemotherapy. 1995; 39:1-8.
9. Stevens DA, Kullberg BJ, Brummer E,. Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Med Mycol. 2000; 38:305-15.
10. Mukherjee PK, Sheehan DJ, Hitchcock CA, et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev. 2005; 18:163-94.
11. Shin S, Pyun MS,. Anti-Candida effects of estragole in combination with ketoconazole or amphotericin B. Phytother Res. 2004; 18:827-30.
12. McElhaney-Feser GE, Raulli RE, Cihlar RL. Synergy of nitric oxide and azoles against Candida species in vitro. Antimicrob Agents Chemother. 1998; 42:2342-6.
13. NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeast, 2nd ed. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa. 2002
14. Rippon, JW. 1988. Medical Mycology. 3rd Edition. W.B. Saunders Co., Philadelphia,USA. 1988
15. NCCLS. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard. Document M38A. National Committee for Clinical Laboratory Standards, Wayne, Pa. 2002
16. Chin NX, Weitzman I, Della-Latta P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 1997; 41:850-852
17. Gardner PR, Gustin MC. Inducible defense mechanism against nitric oxide in Candida albicans. Eukaryot Cell. 2004; 3:715-23.
18. Heald AE, Cox GM, Schell WA, Bartlett JA, Perfect JR. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS. 1996; 10: 263-8.
19. Haque MM, Manzoor N, Hussain ME, Khan LA.. Effect of nitric oxide on H+ -efflux in presence of various nutrients in Candida albicans. Indian J Exp Biol. 2004; 42:86-90.
20. De Groote MA, Fang FC,. NO inhibitions: antimicrobial properties of nitric oxide. Clin Infect Dis. 1995; 21:162-5.
21. Elahi S, Pang G, Ashman RB, Clancy R. Nitric oxide-enhanced resistance to oral candidiasis. Immunology. 2001; 104:447-54.
22. Rossi GR, Cervi LA, Garcia MM. Involvement of nitric oxide in protecting mechanism during experimental cryptococcosis. Clin Immunol. 1999; 90(2):256-65.
23. Porsti I, Paakkari I. Nitric oxide-based possibilities for pharmacotherapy. Ann Med. 1995; 27:407-20.
24. Ullmann BD, Myers H, Chiranand W. A randomized trial of acidified nitrite cream in the treatment of tinea pedis. J Am Acad Dermatol. 1998; 38:559-563.
25. Redding SW, Kirkpatrick WR, Saville S. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J. Clin. Microbiol. 2003; 41:619-622.
26. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991; 43:109-42.
27. Keefer LK, Nims RW, Davies KM, Wink DA. "NONOates" (1-substituted diazen-1-ium-1, 2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol. 1996; 268:281-93.
28. Maragos CM, Morley D, Wink DA, Dunams TM, Saavedra JE, Hoffman A, Bove AA, Isaac L, Hrabie JA, Keefer LK. Complexes of .NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J Med Chem. 1991; 34: 3242-7.
29. Mooradian DL, Hutsell TC, Keefer LK. Nitric oxide (NO) donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro. J Cardiovasc Pharmacol. 1995; 25:674-8.
30. Drago RS. Reactions of nitrogen (II) oxide, free radicals in organic chemistry. Advances in chemistry series, no.36. American Chemical Society, Washington, D.C. 1962
31. Pfaller MA., Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J. Clin. Microbiol. 2003; 41:2176-2179.
32. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N. Engl. J. Med. 1989; 321:794-799.
33. Diamond RD. Cryptococcus neoformans, in: Principles and Practice of Infectious Diseases (Eds. G.L. Mandel, J.E. Bennett and R. Dolin), pp. 2331-2340. Churchill Livingston, Inc.; New York, NY. 1995
34. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 1994; 330:263-272.
35. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 1998; 11:382-402.
36. Young LY, Hull CM, Heitman J. Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. Antimicrob Agents Chemother. 2003; 47:2717-2724.
37. Favre B, Ghannoum MA, Ryder NS. Biochemical characterization of terbinafine-resistant Trichophyton rubrum isolates. Med. Mycol. 2004; 42:525-9.